title: Case report: Inadvertent intra-arterial injection during sclerotherapy may not be the disaster you think.
abstract: OBJECTIVE
  Inadvertent intra-arterial injection is a rare and serious complication of sclerotherapy. Multiple treatments have been used in reported cases, with varying levels of success. We report a rare case of intra-arterial injection being treated with steroids and pulsed dye laser therapy and present a plan for future incidences.
  A 52-year-old woman presented to the clinic looking for aesthetic improvement to telangiectatic veins on the anterior aspect of the right leg. She developed cutaneous necrosis after sclerotherapy injection with 4 mL of 0.5% liquid polidocanol.
  
  
  RESULTS
  After 23 months of pulsed dye laser therapy and a course of oral prednisolone, the patient made a good recovery and is left with minimal lasting tissue damage.
  
  
  CONCLUSIONS
  More research is needed into the area of treating cutaneous necrosis with a pulsed dye laser, but this case report indicates a possible future therapeutic use after a successful outcome.
authors.affiliation: University of Nottingham Medical School, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom.
authors.forename: Paul
authors.initials: P
authors.lastname: Thomas
authors.affiliation: The Mapperley Park Clinic, Nottingham, United Kingdom.
authors.forename: Jo
authors.initials: J
authors.lastname: Martin
authors.affiliation: The Mapperley Park Clinic, Nottingham, United Kingdom; Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, United Kingdom. Electronic address: bruce.braithwaite@nhs.net.
authors.forename: Bruce
authors.initials: B
authors.lastname: Braithwaite
mesh_terms: D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial / Q000379:methods*; D053685:Laser Therapy / Q000379:methods; D007866:Leg / Q000098:blood supply; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012597:Sclerosing Solutions / Q000009:adverse effects* / Q000627:therapeutic use; D015911:Sclerotherapy / Q000009:adverse effects*; D013684:Telangiectasis / Q000628:therapy*
chemical_list: D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols